The aim of this webinar is to revisit latest evidence on secondary preventive effect of SGLT2 inhibitor drugs.
The key learning objectives will be;
- To discuss the cardioprotective effects of SGLT2 inhibitors in terms of heart failure.
- To discuss the effect of SGLT2 inhibitors on kidney function
|WelcomeLearning objectivesIntro/Bio Speakers||Dr. Samuel Seidu, chair (U.K.)|
|Heart failure and SGLT2 inhibitor therapy beyond the presence of diabetes||Dr. Xavier Garcia Moll (ES)|
|SGLT2 inhibitors and the kidney: matter of controversy||Dr.David Wheeler (UK)|
|Question and answers||All|